Wade T. Iams

Management of Adverse Events Associated with MET TKIs in Patients with Advanced NSCLC: A Podcast Discussion

MET exon 14 (METex14) skipping is observed in approximately 3–4% of patients with non-small-cell lung cancer (NSCLC). These patients are typically older and may or may not have a history of tobacco use. Several small molecule MET tyrosine kinase inhibitors (TKIs) have been develo...